Versant Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Versant Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14	Closed	-$506	–	2094
2023 Q2	$506	Buy	14 +9	+180%	+$371	﹤0.01%	1833
2023 Q1	$186	Sell	5 -14	-74%	-$630	﹤0.01%	1726
2022 Q4	$861	Sell	19 -34	-64%	-$2.2K	﹤0.01%	1328
2022 Q3	$4K	Buy	53 +29	+121%	+$2.15K	﹤0.01%	938
2022 Q2	$2K	Buy	+24	New	+$1.53K	﹤0.01%	1175
2022 Q1	–	Sell	-59	Closed	-$9K	–	1678
2021 Q4	$9K	Hold	59	–	–	﹤0.01%	742
2021 Q3	$10K	Buy	59 +55	+1,375%	+$8.85K	﹤0.01%	710
2021 Q2	$1K	Hold	4	–	–	﹤0.01%	1403
2021 Q1	$1K	Buy	+4	New	+$792	﹤0.01%	1476
2020 Q1	–	Sell	-9	Closed	-$1K	–	1767
2019 Q4	$1K	Sell	9 -3	-25%	-$289	﹤0.01%	1303
2019 Q3	$0	Buy	+12	New	+$1.13K	﹤0.01%	1649
2019 Q2	–	Sell	-4	Closed	–	–	1777
2019 Q1	$0	Buy	+4	New	+$272	﹤0.01%	1782

Other funds holding MRTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Versant Capital Management's MRTX Position: Q3 2023 in Review

Versant Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 14 shares — an estimated $506 sold.

Versant Capital Management first reported a position in MRTX in Q1 2019 and held it in 12 quarters. The position peaked at $10K in Q3 2021. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Versant Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Versant Capital Management sold 14 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $506.
Versant Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 12 quarters.
Versant Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10K in Q3 2021.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Versant Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.